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Initial evaluation
The emphasis of the initial screening of a 
suspected acute stroke patient is on rapid 
evaluation and diagnosis that adequately 
excludes stroke mimics. Mimics such as 
seizures, migraine, hypoglycaemia and 
psychogenic weakness may account for 
20 - 25% of suspected stroke or transient 
ischaemic attack (TIA) presentations.[1] 
Stroke should be suspected in all patients 
with abrupt onset of neurological symptoms, 
particularly in those with risk factors for 
stroke. Facial drooping, arm drift, speech 
difficulties and time (FAST) score (Table 1) 
is a useful emergency unit screening test to 
improve stroke recognition with acceptable 
sensitivity and specificity. Although it may 
miss atypical presentations, the presence 
of >1 of these signs raises the likelihood of 
stroke by >5 times.[2] 
Initial management of an acute stroke 
(Fig. 1) includes assessment and correction 
of disordered airway, breathing and 
circulation. The next step is to determine 
whether brain reperfusion can be achieved. 
Brain imaging should be performed without 
delay to exclude haemorrhage and mimics. 
An uncontrasted computed tomography 
(CT) brain scan detects fresh intracranial 
haemorrhage very well, but has a poor 
sensitivity for infarction, especially small 
infarcts, posterior fossae involvement, and 
when performed too soon after the event. 
A normal CT brain scan therefore does not 
exclude an acute ischaemic stroke (AIS). 
Diffusion-weighted magnetic resonance 
imaging (MRI) performs better and detects 
approximately one-third of transient attacks 
lasting ˂24 hours and ~90% of acute brain 
infarctions. However, obtaining an MRI scan 
may delay the start of emergency reperfusion 
therapies; an uncontrasted CT brain scan, 
which is frequently more accessible, provides 
the necessary information in most instances.
A targeted neurological (National Insti-
tute of Health Stroke Score (NIHSS)) and 
cardio vascular examination and rapid blood 
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This article provides a practical overview of current medical treatments for acute ischaemic stroke, particularly for those in a busy family 
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ischaemic, caused by vessel stenosis or occlusion, or haemorrhagic, caused by rupture of vessels, resulting in intraparenchymal and/or 
subarachnoid haemorrhage. Transient ischaemic attack is defined as a transient episode of neurological dysfunction caused by focal brain, 
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an acute stroke are as follows: make an accurate assessment and diagnosis, limit the extent of the brain injury, avoid and treat stroke-related 
complications, evaluate the underlying aetiology that is closely linked to the prognosis for recurrent stroke, institute appropriate secondary 
prevention and facilitate post-stroke recovery.




Rapid assessment and brain imaging
Eligible for IV tPA therapy?
Yes                                              No








Antiplatelet therapy Swallow assessment VTE prophylaxis
Expedited diagnostic work-up 
to determine aetiology
Early mobilisation and 
multidisciplinary rehabilitation
Fig. 1. Algorithm of medical management of acute stroke. (IV tPA = intravenous tissue plasminogen 
activator; VTE = venous thromboembolism.)
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glucose test should be performed before the start of reperfusion 
therapy. Further work-up, including blood investigations, an 
electrocardiogram (ECG) and a chest radiograph, should not delay 
treatment.
Acute reperfusion therapies 
Intravenous thrombolysis with alteplase
Whether a given area of ischaemic brain tissue becomes irreversibly 
damaged, i.e. infarcted, depends on both the degree and duration 
of ischaemia, and therefore specific treatments for AIS focus on 
achieving early reperfusion of ischaemic brain tissue. Alteplase, 
a recombinant tissue plasminogen activator (r-tPA), stimulates 
thrombolysis and thereby recanalisation and reperfusion. Intravenous 
alteplase (0.9 mg/kg) given within 4.5 hours of onset of AIS improves 
the odds of having no significant disability at 3 - 6 months by about 
one-third.[3] The benefits of alteplase are proportionately larger 
and the risk of symptomatic brain haemorrhage is lower the earlier 
the treatment is administered after the onset of stroke symptoms. 
Approximately 4.5 patients need to be treated within 90 minutes, 
9 patients between 90 and 180 minutes, and 15 patients between 180 
and 270 minutes after onset of stroke for one of them to have an 
excellent outcome (minimal signs, if any; no disability).[4] Although 
alteplase for AIS does increase the odds of having a symptomatic 
intracranial haemorrhage with an overall risk of ~6%, it does not 
affect overall mortality at 3 months after stroke.[3] Bleeding risk 
increases with elevated serum glucose, evidence of early ischaemic 
changes or a hyperdense middle cerebral artery sign on CT brain 
imaging – higher NIHSS indicating a more severe stroke. However, 
within 4.5 hours of stroke, the likelihood of achieving an excellent 
outcome with r-tPA is greater than the risk of death, with early 
treatment particularly important in patients with large strokes. 
Early administration of alteplase to appropriate patients is therefore 
recommended. This is, however, of particular importance in severe 
stroke, and is more effective if given sooner than later in all eligible 
patients.[4]
Candidates for intravenous thrombolysis should meet the criteria 
for use, which are readily available in stroke guidelines.[5] The benefits 
and risks of r-tPA treatment should be discussed with the patient, if 
competent, or with a family member who is able to make decisions on 
behalf of the patient. Verbal or written consent should be obtained, if 
possible, but in the event that the patient is unable to make medical 
decisions and a suitable family member or decision-maker cannot be 
identified and approached in a timely manner, the judgement of the 
physician may substitute.
Where patients are eligible for intravenous thrombolysis and 
the onset is ≤4.5 hours, they should be treated with alteplase 
even if they are potential candidates for endovascular therapy 
with a stent retriever.[5] Aspirin should be given immediately 
to all patients with AIS, with the exception of those receiving 
intravenous thrombolysis. In the latter, the initiation of aspirin 
should be delayed by 24 hours after r-tPA and only administered 
once a CT brain scan has confirmed the absence of intracranial 
haemorrhage.[5]
Endovascular thrombectomy
Proximal large-vessel occlusions that are amenable to mechanical 
thrombectomy occur in ~10% of AIS.[6] Endovascular thrombectomy 
with stent retrievers (i.e. second-generation devices) performed in 
addition to early alteplase treatment within 6 hours of AIS in 
suitable patients doubles the rate of angiographic revascularisation 
at 24 hours and functional independence at 3 months. This effect 
is seen across the age spectrum and appears to be consistent in 
patients who are ineligible for r-tPA.[7] The number needed to 
treat to achieve one more patient with an independent functional 
outcome is between 3.2 and 7.1.[8] 
General supportive measures in acute 
stroke care
Homeostasis
Restoring and maintaining bodily homeostasis is a key component 
of facilitating recovery after stroke. The following aspects should be 
targeted within the first 72 hours to improve outcomes:
• Airway support and ventilation. This may be acutely necessary 
in patients who have reduced consciousness or bulbar dysfunc-
tion that compromises the airway. Supplemental oxygen is not 
beneficial in patients with AIS who maintain normal oxygen 
saturation. 
• Blood pressure (BP) management. There is insufficient evidence 
to advise management in AIS; however, in general, high BP should 
not be lowered acutely but over the following days to weeks unless 
the patient is severely hypertensive (>220 mmHg systo lic BP) or 
hypertensive complications are present. Causes of low BP should 
be sought and corrected. 
• Temperature. Fever is associated with worse outcomes; therefore, 
antipyretics might be of benefit.
• Blood glucose. Hypoglycaemia can mimic a stroke and should 
be rapidly corrected. Hyperglycaemia is associated with worse 
outcomes, and judicious lowering of blood glucose levels is 
recommended.
• Screening and formal swallow assessment. Up to 50% of stroke 
patients have dysphagia, and early detection and management 
may prevent aspiration pneumonia and improve outcomes. 
Swallowing function should be assessed within the first 24 hours 
after stroke, keeping the patient nil per os on intravenous saline 
until they have been evaluated for nasogastric tube feeding, 
which may be necessary if significant dysphagia is present. 
• Adequate hydration and nutrition. Decent early nutrition is asso -
cia ted with a lower rate of pressure sores.
Stroke-unit care
Stroke patients have better odds of being alive, independent and at home 
1 year after the event when they are treated in a dedicated stroke unit that 
has a multidisciplinary team, including trained nursing staff, doctors, 
occupational therapists, physiotherapists, speech and language therapists 
and dieticians.[9] When the population-level effect of stroke-unit care is 
considered by weighing the annual number of people in a population 
who are likely to have a stroke, eligible to receive this intervention and the 
potential benefit from the intervention (in terms of additional survivors 
independent in daily activities), several studies suggest that a basic model 
of stroke-unit care may be the most effective for improving independent 
survival. Although most of the evidence for the stroke-unit model of care 
comes from higher-income countries, limited reports from developing 
countries show similar benefit.[10] Avoidance of complications, improved 
Table 1. Face, arm, speech and time (FAST) test 
Face Ask the person to smile. Does one side of the 
face droop?
Arm Ask the person to raise both arms. Does one arm 
drift downwards?
Speech Ask the person to repeat a simple phrase. Is the 
speech slurred or strange?
Time If you observe any of these signs, call for an 
ambulance immediately
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supportive care, earlier mobilisation and rehabilitation efforts may 
account for these better outcomes. 
Avoiding and treating acute 
complications
Medical complications after stroke occur frequently and should be 
avoided where possible and treated effectively when they occur. 
Venous thromboembolism might be the cause of ~10% of stroke 
deaths. Therefore, deep vein thrombosis (DVT) prophylaxis and 
pressure care for patients immobilised by stroke are priorities. 
While graduated compression stockings are not effective, thigh-
length intermittent pneumatic compression prevents DVT and 
improves survival at 6 months. Low-dose subcutaneous low-
molecular-weight heparin has been used for DVT prevention but 
should be avoided, as the overall increased risk of symptomatic 
intracerebral haemorrhage is higher than the risk of pulmonary 
embolism. In selected high-risk patients, such as those with 
previous venous thromboembolism or morbid obesity, it may still 
provide some benefit. 
Life-threatening cerebral oedema may occur after a large cerebral 
infarction. This may complicate large strokes, particularly in younger 
patients who have less age-related atrophy, and hence manifest 
with critically raised intracranial pressures. Early decompressive 
hemicraniectomy for malignant middle cerebral artery syndrome 
may be life-saving, halving the untreated 80% mortality, but careful 
patient choice and early timing of the procedure are necessary to 
select those with the best chance of surviving with an acceptable 
functional outcome.[11]
Secondary prevention and recovery
All patients with AIS or TIA are in need of urgent secondary 
prevention. Untreated, after AIS and TIA, the risk of recurrent stroke 
is ~10% at 1 week, 15% at 1 month, and 18% at 3 months.[12] In some 
individuals, e.g. those with recent atherosclerotic symptoms, the 
risk is even higher. Various scoring systems have been proposed to 
identify patients at high risk of early stroke recurrence in primary care 
or emergency unit settings to fast-track them for urgent treatment. 
The age, blood pressure, clinical features, duration and diabetes 
(ABCD2) score has been widely used, with a score of ≥4 denoting 
high risk (Table 2). However, the ABCD2 score has drawbacks, neither 
distinguishing between strokes and mimics nor accurately identifying 
all high-risk patients. One-fifth of all TIA patients who scored ˂4 
(classified as low risk), were found to have either significant carotid 
stenosis or atrial fibrillation requiring urgent interventions. The age, 
blood pressure, clinical features, duration and diabetes plus dual 
TIA and imaging (ABCD3-I) scoring system (Table 2) improves the 
detection of patients at high risk, incorporating those with 2 TIAs 
in 1 week, but the score also requires brain and carotid artery vessel 
MRI scans and therefore is harder to use in primary care settings or 
secondary level hospitals, where many patients may first be seen. 
Evidence clearly shows that most recurrent strokes occur within 
days after the index event. Timely initiation of appropriate secondary 
prevention by stroke specialists reduces the rate of stroke recurrence by 
80%.[13] Choice of secondary prevention differs, depending on whether 
the stroke is thought to be of arterial or cardiac origin. Therefore, the 
aim of a diagnostic work-up after a stroke is to determine the most 
likely underlying aetiology to optimise treatment choice.
Prevention of recurrent ischaemic strokes due to 
arterial disease
Antiplatelet therapy
Aspirin commenced immediately after a stroke at doses of 160 - 300 mg 
per day decreases early recurrent strokes by half within the first 6 - 
12 weeks.[14] Longer-term antiplatelet treatments that are effective 
in reducing the risk of stroke include daily aspirin 75 - 150 mg or 
clopidogrel 75 mg or twice-daily aspirin 25 mg plus extended-release 
dipyridamole 200 mg. Dual antiplatelet treatment appears to be even 
more effective than aspirin in preventing early stroke recurrences 
in minor stroke (NIHSS <4) and TIA. In a large Chinese study,[15] 
the early use (<3 days) of a combination of aspirin (75 - 300 mg 
loading dose, then 75 mg) and clopidogrel (300 mg loading dose, then 
75 mg) for 3 weeks, followed by clopidogrel alone for 3 months and 
thereafter monotherapy with either aspirin or clopidogrel, reduced 
the risk of early recurrent stroke at 90 days by one-third (6% v. 9%) 
compared with aspirin monotherapy, without increasing the risk 
of major bleeding. Recently, a similar international study showed 
that aspirin plus clopidogrel (600 mg loading dose, then 75 mg) for 
90 days in minor stroke and high-risk TIA (ABCD2 ≥4) decreased 
recurrent stroke by 25%, albeit with an increased risk of major 
bleeding (0.9% v. 0.4%), compared with aspirin alone.[16] Therefore, 
early dual antiplatelet therapy appears to be effective in TIA and 
minor strokes, but its role is not established in cardioembolic or more 
severe strokes. Moreover, longer-term dual antiplatelet treatment for 
˂1 year after stroke does not reduce stroke recurrence compared with 
Table 2. ABCD2 and ABCD3-I scores
Score variables ABCD2 score ABCD3-I score
Age (≥60 years) 1 1
Blood pressure (≥140/90 mmHg) 1 1
Clinical features of TIA
Speech impairment only 1 1
Unilateral weakness 2 2
Duration of TIA 
10 - 59 min 1 1
≥60 min 2 2
Diabetes mellitus 1 1
Dual TIA (index TIA plus ≥1 other TIA in past 7 days) - 2
Imaging criteria
Ipsilateral ≥50% ICA stenosis - 2
Acute diffusion-weighted imaging hyperintensity - 2
Total range of score points 0 - 7 0 - 13
ABCD2 = age, blood pressure, clinical features, duration and diabetes; ABCD3-I = age, blood pressure, clinical features, duration and diabetes plus dual TIA and imaging; 
TIA = transient ischaemic attack; ICA = internal carotid artery.
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monotherapy, and has a higher risk of major bleeding; it is therefore 
not recommended. 
Carotid artery revascularisation
In patients with recent, symptomatic extracranial atherosclerotic 
carotid stenosis >70 - 99%, carotid endarterectomy (CEA) halves 
the 5-year risk of stroke and death compared with best medical 
treatment of >2 decades ago. For moderate stenoses (50 - 69%), this 
risk is reduced by a quarter. Carotid stenting has higher rates of 
periprocedural stroke and death than CEA in patients >70 years of 
age, lower rates of local complications than CEA, but similar rates 
of longer-term stroke, death and functional outcome.[17] If carotid 
revascularisation is to be performed, it should be done within 1 week 
of stroke or TIA, after which time benefit has not been demonstrated. 
Intracranial and vertebral artery stenting do not compare favourably 
with optimal medical treatment, with unacceptably high rates of 
periprocedural stroke and death. 
Prevention of recurrent ischaemic strokes due to 
cardioembolism
Antithrombotic therapy
Anticoagulation does not reduce the early risk of stroke of arterial 
origin, even in patients with a high risk of thrombosis; it is also not 
more effective than antiplatelet agents in cervical arterial dissection. 
However, anticoagulation can dramatically lower stroke recurrence 
rates in certain settings. Patients with atrial fibrillation (AF) are 
frequently at high risk of recurrent stroke. Higher congestive heart 
failure, hypertension, age, diabetes, and stroke/TIA  (CHA2DS2)-
vascular disease (VASc) scores are associated with a higher risk 
of stroke in non-valvular AF and may be used to estimate risk in 
individual patients and to evaluate when to commence anticoagulation 
(Table 3). Most major guidelines recommend anticoagulation with an 
annual stroke risk of >1 - 2%. After stroke or TIA, the use of warfarin, 
aiming for an international normalised ratio (INR) of 2 - 3, reduces 
the risk of recurrent stroke by two-thirds. Direct oral anticoagulants, 
such as dabigatran and rivaroxaban, reduce stroke recurrence in 
non-valvular AF by a further 15% compared with warfarin, without 
increasing major bleeding. It is not clear when the best time is to 
start oral anticoagulation after stroke. For confirmed TIAs, it may 
be reasonable to start immediately. In AIS, it is most likely between 
4 and 14 days, depending on risk of stroke recurrence (which may 
be estimated by CHA2DS2-VASc scores (Table 3), infarct size and 
presence of haemorrhagic conversion. 
Because of the significant benefits of anticoagulation in preventing 
stroke in non-valvular AF, an effort should be made to detect 
paroxysmal AF using prolonged ECG monitoring. Other high-risk 
cardiac diseases, such as recent myocardial infarction, rheumatic 
valve disease and dilated cardiomyopathies, may be present and also 
necessitate anticoagulation or other specific interventions. These 
conditions should be identified by an adequate cardiac work-up, 
especially if there are clinical or radiological features suggesting a 
cardioembolic infarction, such as sudden onset to maximal deficit, 
aphasia without hemiparesis, a Valsalva manoeuvre at the time of 
stroke onset, co-occurrence of cerebral and systemic emboli or acute 
multiple infarcts in multiple cerebral territories.
Lowering of blood pressure
Sustained lowering of BP prevents stroke recurrence, which may be 
reduced by ~20% if the lowering of BP by ~5 mmHg systolic and 
2.5 mmHg diastolic is maintained. Even more strokes are prevented 
if more intensive BP reductions are achieved. 
Lowering of blood cholesterol concentrations
The use of statins to lower low-density lipoprotein (LDL) cholesterol 
by 1 mmol/L decreases the risk of recurrent stroke by 12%, with more 
intensive LDL reductions showing even further reduction in stroke 
risk, although the optimum target is not yet known. 
Modification of other vascular risk factors and lifestyle
Lifestyle modifications that are recommended after stroke include 
weight loss, smoking cessation, low alcohol use, a low-risk diet such 
as the Mediterranean diet, and regular physical exercise. Hormone 
therapy in postmenopausal women increases the risk of recurrent 
stroke by about 25%; it should therefore be discontinued, if possible. 
Conclusion
Rapid and accurate assessment and early initiation of suitable therapies 
are essential in the management of patients with AIS to limit brain 
injury and increase disability-free survival. Reperfusion therapies, 
such as intravenous thrombolysis and, more recently, endovascular 
therapies, improve functional outcomes, often substantially. Because 
of the time-sensitive nature of AIS and the potential to limit brain 
injury, it is crucial that stroke services are well organised, including 
ready access to primary and comprehensive stroke centres with 
appropriate triage and early management of TIA and stroke. Stroke-
unit care may be the most effective population-level intervention for 
achieving better functional outcomes, as all patients are eligible for 
this option. Careful avoidance and treatment of complications, such as 
aspiration, are recommended. A diagnostic work-up to determine the 
underlying aetiology of stroke should be expedited to inform urgent 
secondary prevention. Early aspirin and dual antiplatelet therapy 
for minor atherosclerotic strokes or TIAs are more effective than 
previously recognised in preventing early recurrent stroke. Newer 
oral anticoagulants have proved to be more effective than warfarin in 
Table 3. CHA2DS2-VASc score for estimating annual stroke 
risk for non-valvular atrial fibrillation in adults
Condition Points
C Congestive heart failure 1
H Hypertension 1
A2 Age ≥75 years 2
D Diabetes mellitus 1
S2 Prior stroke or TIA or 
thromboembolism
2
V Vascular disease (peripheral, 
MI, aortic plaque)
1
A Age 65 - 74 years 1
Sc Sex category (i.e. female) 1
Total range of score points 0 - 9











CHA2DS2-VASc = congestive heart failure, hypertension, age, diabetes and stroke/TIA-
vascular disease; TIA = transient ischaemic attack; MI = myocardial infarction.
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cardioembolic stroke prevention and have better safety profiles. Early 
mobilisation and multidisciplinary team input in acute rehabilitation 
are recommended to facilitate optimal post-stroke recovery. 
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